share_log

Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial

Moomoo 24/7 ·  Mar 5 08:06

– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter –

– Approximately 50% of participants have compensated cirrhosis –

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment